Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023. 2. Planned or actual hematopoietic stem cell transplantation (HSCT). 3. Provision of signed willing to sign a consent form. Who Should NOT Join This Trial: 1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons. 2. Substance abuse compromising adherence. 3. Any condition judged by investigators to jeopardize safety or compliance. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023. 2. Planned or actual hematopoietic stem cell transplantation (HSCT). 3. Provision of signed informed consent. Exclusion Criteria: 1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons. 2. Substance abuse compromising adherence. 3. Any condition judged by investigators to jeopardize safety or compliance.

Locations (1)

Affiliated Hospital of Qinghai University
Xining, Qinghai, China